Biotechnology

Beyond Ventures' first investment, Prenetics, becomes first Hong Kong unicorn to go public

HONG KONG, Sept. 16, 2021 /PRNewswire/ -- Hong Kong-based venture capital firm Beyond Ventures is pleased to support today's announcement by the firm's first investee company, Prenetics, that Prenetics, a global leader in genomic and diagnostic testing is set to merge with Artisan Acquisition Cor...

2021-09-16 15:31 2840

GeneQuantum announces two key leadership appointments

SUZHOU, China, Sept. 15, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry-leading biotech company dedicated to the next generation bioconjugate drugs based on the innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announced the appointment of Dr.Li Wan as the ...

2021-09-16 09:00 1979

SuperTrans Medical supported by U.S. National Institutes of Health (NIH) in developing its lead antibiotic against urgent threat drug resistant bacteria

SYDNEY, Sept. 16, 2021 /PRNewswire/ -- SuperTrans Medical ("STM"), a biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multi-drug resistant bacterial infections, has announced that the U.S. National Institutes of Health (NIH) will be supporting additional dev...

2021-09-16 08:45 3870

Prenetics, a Global Leader in Genomic and Diagnostic Testing, to Become Publicly Traded on the Nasdaq via Merger with Adrian Cheng's Artisan Acquisition Corp.

* Prenetics' mission is to disrupt and decentralise the healthcare industry with a global opportunity of overUS$1.3 trillion. * Prenetics' multi-product healthcare ecosystem strategy is driven by prevention focused genomic testing, rapid diagnostics for COVID-19 and infectious diseases, and c...

2021-09-16 06:00 9701

New Therapy to Treat Advanced Small Cell Lung Cancer Approved for Australian Patients

Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved to treat second-line metastatic SCLC inAustralia in more than 20 years * * ZEPZELCA approval granted under a provisional regulatory pathway * US FDA and TGA collaborated via 'Project Orbis' to accelerate avail...

2021-09-14 18:57 2313

Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H

FREIBURG, Germany, Sept. 14, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases. Eleva has ordered four more state-of-the-a...

2021-09-14 10:30 2301

PharmAbcine to Participate in ACCESS CHINA Biotech Forum

DAEJEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in ACCESSCHINA Biotech Forum. The event will...

2021-09-13 20:00 1910

RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval

The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care Number of U.S. sites for the study has also been expanded RHB-107, a nov...

2021-09-13 19:00 7026

FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics enter manufacturing agreement to rapidly advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke

STATE COLLEGE, Pa., Sept. 13, 2021 /PRNewswire/ -- * FUJIFILM Diosynth Biotechnologies (FDB) will provide essential drug substance and drug product manufacturing, under accelerated timelines, for NeuExcell's first-in-human clinical studies * Drug substance manufacturing will be carried out in...

2021-09-13 18:00 2467

Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors

HOUSTON and SINGAPORE, Sept. 13, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a Phas...

2021-09-13 17:00 2228

Everest Medicines Enters into Comprehensive Agreements with Providence Therapeutics to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Asia Emerging Markets

SHANGHAI, Sept. 13, 2021 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest" or the "Company") announced today two separate definitive agreements ("Agreements") withProvidence Therapeutics Holdings Inc.

2021-09-13 17:00 5720

Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral Initiative

INCHEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, announced the signing of an MOU today to participate in the Frontier 1.5D initiative to develop a climate risk management model as part...

2021-09-13 12:41 2682

Cytiva triples single-use consumables capacity in China

* Three new manufacturing lines were successfully launched in under ten months, with an additional eight new lines planned to launch in Q3 2022. * Sustain and secure the supply chain for customers in China and the broader region.   * With the use of Fortem™ film, Cytiva helps customers speed...

2021-09-10 16:33 4148

PharmAbcine Announces Joint Patent Application with MSD for the Treatment of Cancer

DAEJEON, South Korea, Sept. 9, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today announced it submitted a Patent Cooperation Treaty (PCT) application for the combination therapy of...

2021-09-09 20:00 2429

Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 Vaccine

CHENGDU, China, Sept. 9, 2021 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover) , a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that its wholly-owned subsidiary, Zhejiang Clover...

2021-09-09 19:51 3259

ABILITY Diabetes Global enrolls thousandth patient: A Cardinal Milestone Achieved

TAMPA, Fla., Sept. 9, 2021 /PRNewswire/ -- ABILITY Diabetes Global  (Randomized Comparison ofAbluminus DES+ Sirolimus-Eluting Stents versus Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diabetes Mellit...

2021-09-09 19:26 4202

PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation

CAMBRIDGE, Mass., Sept. 9, 2021 /PRNewswire/ -- PAQ Therapeutics ("PAQ"), a biotechnology company harnessing the power of autophagy to restore health and cure disease, and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced tha...

2021-09-09 19:20 3267

China's Northernmost Free Trade Zone Sees Wider Reform and Opening-up

HARBIN, China, Sept. 9, 2021 /PRNewswire/ -- August 30 marks the second anniversary of the establishment of Harbin sub-area ofHeilongjiang pilot free trade zone (FTZ). Over the past two years, a total of 8,787 new enterprises have been established inHarbin sub-area. Nearly one-third of the enterp...

2021-09-09 18:12 2918

China's Northernmost Free Trade Zone Sees Wider Reform and Opening-up

HARBIN, China, Sept. 9, 2021 /PRNewswire/ -- August 30 marks the second anniversary of the establishment of Harbin sub-area ofHeilongjiang pilot free trade zone (FTZ). Over the past two years, a total of 8,787 new enterprises have been established inHarbin sub-area. Nearly one-third of the enterp...

2021-09-09 18:06 3096

Biokangtai: Recombinant COVID-19 Vaccine(Adenovirus Vector) licensed for manufacturing, which actively promotes vaccine export and improves vaccine accessibility

SHENZHEN, China, Sept. 8, 2021 /PRNewswire/ -- The other day Shenzhen Kangtai Biological Products Co., Ltd. announced that the company and AstraZeneca signed the "Amendment 1 to License Agreement". In addition to authorizing BIOKANGTAI to commercialize its Recombinant COVID-19 Vaccine(Adenovirus ...

2021-09-09 11:40 4559